MEDINCELL: management transactions · France · AMF

About MEDINCELL

Medincell is a French next-generation biopharmaceutical company focused on the development of long-acting injectable therapies. Listed on Euronext Paris under the ticker MEDCL and identified by ISIN FR0004065605, the company was founded in Montpellier in 2007 and has built its strategy around a clear ambition: to improve treatment adherence, enhance therapeutic performance, and broaden access to medicines through controlled-release technologies. Its headquarters are located in Jacou, in the Montpellier area, placing Medincell within one of France’s most established life-science ecosystems. Medincell’s business model is centered on its proprietary BEPO® technology, and on the licensed SteadyTeq™ name used in its partnership with Teva. This platform enables a drug to be released at a controlled rate over several days, weeks, or months after a subcutaneous or local injection, using a small bioresorbable depot. In practical terms, Medincell develops customized formulations designed to address specific medical needs, with each product relying on a unique polymer combination. The company therefore positions itself primarily as a technology and formulation innovator rather than a conventional direct-selling pharmaceutical company. The first major product developed from this platform is UZEDY®, a risperidone-based antipsychotic approved by the U.S. FDA in 2023 for the treatment of schizophrenia in adults and commercialized in the United States by Teva. UZEDY is strategically important because it demonstrates Medincell’s ability to turn formulation innovation into an industrial product with global commercial relevance. In 2025, the company also announced approvals for this risperidone LAI in Canada and South Korea under the LONGAVO® brand, while Teva reported strong growth in UZEDY net sales in 2025. In parallel, the olanzapine LAI program reached another milestone when the FDA accepted the NDA in February 2026, underscoring the depth of the pipeline. Medincell operates a licensing-driven business model built on partnerships with major pharmaceutical companies. This structure generates royalties on worldwide sales and milestone payments while reducing the capital intensity of maintaining a large commercial organization. The company has an international footprint through its partnerships, especially with Teva, and actively participates in investor conferences in the United States and Europe. Its positioning as a “clinical- and commercial-stage biopharmaceutical licensing company” makes it a distinctive player in the French market, combining pharmaceutical innovation, technology transfer, and intellectual property monetization.